Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAIN study of obinutuzumab maintenance versus observation after obinutuzumab + bendamustine induction in follicular lymphoma
jRCT1031210379Phase 3Suspended
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of obinutuzumab and bendamustine in follicular lymphoma (FL) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: progression-free survival. Started Oct 2021; status: suspended.
02
Drugs
obinutuzumabbendamustine
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT1031210379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031210379.